BALVERSA®
(erdafitinib)
BALVERSA® (erdafitinib)
BALVERSA - pivotal clinical trial publications
BLC-3001 (THOR)
Loriot Y, Matsubara N, Park SH, et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med. 2023;389:1961-1971.
Loriot Y, Matsubara N, Park SH, et al. Supplement for: Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med. 2023;389:1961-1971.
Loriot Y, Matsubara N, Park SH, et al. Protocol for: Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med. 2023;389:1961-1971.
BLC-2001
Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338-348.
Loriot Y, Necchi A, Park SH, et al. Supplementary appendix: Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338-348.
Loriot Y, Necchi A, Park SH, et al. Protocol for: Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338-348.
Siefker-Radtke AO, Necchi A, Park SH, et al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. [published online ahead of print January 11, 2022]. Lancet Oncol. 2022. doi: 10.1016/S1470-2045(21)00660-4.
Plain language summaries of pivotal clinical trials
BLC-2001
Loriot Y, O'Hagan A, Siefker-Radtke AO. Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-up. Future Oncol. 2023 Nov 2. doi: 10.2217/fon-2023-0596.